Home
About
Overview
Sharing Data
ORCID
Help
History (1)
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012 Aug 15; 72(16):3928-37.
View in:
PubMed
subject areas
Animals
Combined Modality Therapy
Female
Humans
Immunotherapy, Adoptive
Indoles
Lymphocyte Activation
Male
Melanoma
Melanoma, Experimental
Mice
Mice, Inbred C57BL
Mice, Transgenic
Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf
Sulfonamides
T-Lymphocytes
Tumor Cells, Cultured
authors with profiles
Thinle Chodon
Richard Koya